ProfileGDS5678 / 1445460_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 74% 74% 73% 74% 76% 76% 74% 74% 74% 75% 74% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9440975
GSM967853U87-EV human glioblastoma xenograft - Control 24.843274
GSM967854U87-EV human glioblastoma xenograft - Control 34.8984274
GSM967855U87-EV human glioblastoma xenograft - Control 44.8585673
GSM967856U87-EV human glioblastoma xenograft - Control 54.8875774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9339576
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0326376
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8728174
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8542574
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.866174
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8915375
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9295574
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.927575
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8920275